work diversifi de-risk ep
reiter buy think stori continu improv better visibl
patent biosimilar competit new pipelin drug come kra
tezepelumab asthma less concentr one franchis seem
alway hamper larg biotech peer otezla diversfi biz
biosimilar biz play see price-to-earnings ep pot
pictur much may perceiv good bad thing depend
ask see evolv concentr biotech big pharma
diversifi biz good biotech live one big cash cow earli
cycl busi approach end cycl reliant
one drug mani biotech peer experienc trade
year investor uncertainti biosimilar risk neulasta
patent risk enbrel see pot price-to-earnings expans toward median pharma
peer pharma like given less reliant one product diversifi
decent pipelin bottom line growth pharma ok
see prior flat-to-down rev ep resili diversifi
oteza biosimilar biz new driver simpli see
ep get time thesi play
short-to-medium term come understand street may see whole lot
near-term catalyst whole kra euphoria play bit short term
mostli similar data kra continu focu spring
next read-out co say data-rich year kra combo predict pot
pivot phase iib read stock also run toward all-tim high
note guid littl bit invest year higher opex see
also note management comment around phase ii bcma seemingli
non-commit go pivot need see data make us slightli nervou
front could good blue/celg
drill littl mix like good enough
detail insid ep lower vs con guidanc
base guidanc opex increas q/q though
could conserv
import look assum guidanc jan conserv
somewhat invest year alway seem expect street
time come around base higher opex given otezla salesforc
spend pipelin launch prep new product somewhat guid
alreadi tweak ep lower vs con due higher
opex meanwhil rev in-lin consensu includ otezla
tend conserv initi guidanc could see management
guid ep revenu
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
price target base appli
multipl ep
view lower-risk lower-beta higher
visibl biotech move higher benefit
biotech sector see posit rotat
believ consensu estim gener low
next year
upsid scenario price target base
appli multipl non-gaap ep
kra play significantli faster
better expect
bite platform includ surpris
posit tezepelumab data late
market product prove resili
downsid scenario price target base
appli multipl non-gaap ep
greater-than-anticip competit mylan
neulasta biosimilar
higher expect price pressur enbrel
slower expect sale reimburs
aimovig launch trajectori neg affect
disappoint pipelin program includ
kra bite tezepelumab
kra oncolog program could surpris upsid
bite t-cell engag platform garner attent
next month w/ new data releas
see potenti balanc sheet deploy
aimovig launch trajectori continu strong
believ repatha continu see volum growth
new ndc decreas script abandon rate
think eros entranc neulasta
biosimilar may over-st
new bcma data prove compet
celg
kra program
monotherapi combin oncolog
phase tezepelumab asthma data
bolt-on larg hedg biosimilar
risk add emerg market exposur
pleas see import disclosur inform page report
big pictur continu diversifi otezla ad
pipelin product includ kra bcma tezepelumab moreov biosimilar
busi alreadi run rate consensu view low
de-risk enbrel ip patent issu behind us mostli kra efficaci yesterday
competitor kra overhang pass behind us fine w/ worst case
play deploy otezla accret deal possibl bd bolt-
on urgent price-to-earnings expans low may continu
ep vs con driven slightli higher revenu vs con
guidanc rais toward high end slightli see chart
mostli consensu alreadi go number point
neulasta us light largest miss slide point qq unit declin
onpro biosimilar competit watch bear keen
enbrel beat big due favor account chang benefit
aimovig weaker vs con although explain neg
chang account impact biosimilar biz notabl much higher vs
con annual alreadi alreadi almost blockbust statu
new bone drug even romo also nice alreadi beat consensu
remind investor street modest number drug
new materi commentari kra phase ii enrol well
combin enrol next data readout known alreadi colorect cancer
remain low expect area co make decis next step data matur
rais revenu con midpoint
guidanc larg due higher enbrel biosimilar sale estim
slightli off-set lower repatha aimovig project
revis ep estim lower vs con guidanc
base management guidanc expect opex increas q/q
pleas see import disclosur inform page report
compani report jefferi
compani report jefferi
pleas see import disclosur inform page report
timingexpect news regulatori decis biosimilar infliximababp data updat bcma bite data patient egfrv posit glioblastoma phase data hle bite patient r/r aml bla biosimilar rituximab abp inflammatori diseas mutein data tezepelumab adult adolesc sever dose escal data mcrpc psma hle-bit prostat cancer dose escal data hle bcma bite updat includ data updat clinic hold phase data inhibitor iv mm aml updat clinic hold phase data inhibitor oral mm aml phase data hle bite patient r/r aml biosimilar portfolio kanjinti amgevita remicad abp rituxan abp erbitux data bite blincyto phase data bite aml data once-weekli administr relaps refractori mm arrow kyproli data vs kd relaps refractor mm candor kyproli phase data hle-bit patinet nsclc phase data hle-bit patient r/r aml phase studi lp sirna phase ii data systemat lupu erythematosu phase data abp biosimilar soliri abp phase ii data tezepelumab patient atop dermatitistezepelumabproductstag indication/tri infotarget/mechanismpartnerkyproli carfilzomib phase combo rrmm arrow proteasom inhibitor anti-prolif pro-apoptoticomecamtiv mecarbilphas chronic heart failurecardiac myosin activatorcytokinet servier eu royalti blincyto blinatumomab phase ii/dlbclbi-specif mab ii/asthma atop dermatitismab anti-thym stromal lymphopoietin tslp aznimlyg t-vec phase ib/metastat melanomavir deriv gm-csf iiceliac mabprovent bio i/iisolid tumorskra inhibitor i/iimmbispecif cell engag bite target inhibitor iv inhibitor oral bispecif ab iinflammatori mutein fc fusion protein crohn ucundisclos ismall-cel lung bite iprost cancerpsma hle-bit iobesityundisclos ir/r amlextend halflif bite immextend half-lif anti-bcma bite iglioblastomabispecif probodi mab target egfr isclcdll car-t iprost cancerbispecif cell engag bite target psma immbispecif cell engag bite target iamlextend half-lif bite target irespiratori mab inhlextend half-lif bite target isystem lupu erythematosusanti-baff/icosl bispecif abazn iheart failureselect cardiac troponin activatorcytokinet icardiovascular diseasesirna lipoprotein exhibit ep comparison tabl
ep beat higher revenu gener in-lin expens product sale
quarter came consensu due mix variou product beat
enbrel came consensu flat q/q higher net sell price
posit chang account estim
neulasta declin q/q came lower consensu us
sale lower consensu attribut increas biosimilar
competit
pleas see import disclosur inform page report
aimovig sale quarter consensu q/q
q/q declin partial attribut unfavor chang account
estim greater number medicaid patient receiv drug initi
anticip note overal health franchis well paid
demand increas
repatha came gener line consensu grew q/q driven q/
 volum growth volum growth off-set declin net sell price
follow introduct new low price repatha late note
lower list price repatha repres major total prescript recent
announc plan discontinu origin list price sku repatha decemb
also highlight prescript requir attest
approv rate us
amgn biosimilar franchis came handili beat consensu estim
beat primarili driven launch kanjinti herceptin
biosimilar msavi avastin biosimilar good start
amgn biosimilar franchis annual
newest product launch even came consensu repres
growth q/q major sale quarter driven sale japan
note even receiv perman us j-code facilit greater
uptak futur
sensipar sale came consensu repres declin
q/q y/i due primarili impact at-risk gener launch note
on-going litig uncertainti outlook sensipar go forward parsabiv
also came low consensu adopt larg dialysi center appear
slower initi anticip
prolia sale line consensu q/q sale expect
prolia heavili impact typic season
aranesp epogen beat consensu respect epogen declin
q/q y/i aranesp flat q/q y/i net sell price
product continu pressur due extend contract dialysi
facil competit
hem/onc kyproli xgeva vectibix nplate other product roughli line
consensu -- grow y/i mostli due unit growth volum
state discontinu earli neurosci research except
neuroinflamm pursu inflamm divis
surfac minim impact market product
major program neurosci requir research engin
howev investor standpoint notabl would suggest area
investor interest like neuropsychiatri compani area unlik interest
compani focu core area compet includ cv inflamm
oncolog make bulk market product pipelin
pleas see import disclosur inform page report
